Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aethlon faces a multitude of challenges that could impede its growth and financial stability. The company has a history of significant losses and anticipates continued financial struggles, necessitating further financing that may dilute current shareholders. Furthermore, Aethlon’s limited experience with large-scale contracts and compliance with manufacturing practices, coupled with competitive pressures and potential obsolescence of its Hemopurifier technology, pose significant operational risks. Regulatory hurdles, potential delisting from Nasdaq, and difficulties in attracting executive talent further compound the risks, making investment in Aethlon’s securities speculative.
Overall, Wall Street has a Moderate Buy consensus rating on AEMD stock based on 1 Buy and 1 Hold.
To learn more about Aethlon’s risk factors, click here.